Intranasal Oxytocin in Pediatric Populations: Exploring the Potential for Reducing Irritability and Modulating Neural
Kennet Sorenson1, Emilee Kendall1, Hannah Grell1
1Department of Psychiatry, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Insights
Intranasal Oxytocin (OXT) shows potential for treating irritability in youth, particularly in autism spectrum disorder (ASD), Prader-Willi syndrome (PWS), and Phelan-McDermid syndrome (PMS). Further research is needed to optimize dosage and patient selection.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Oxytocin (OXT) is an endogenous neuropeptide vital for social behavior and emotional processing.
- Intranasal OXT delivery is common in clinical research for psychiatric disorders, but results are mixed due to limited pharmacokinetic/pharmacodynamic models.
- OXT's mechanism of reducing neural activation in emotional response areas suggests potential for conditions like youth irritability.
Purpose of the Study:
- To review randomized controlled trials (RCTs) of intranasal OXT in pediatric patients with Autism Spectrum Disorder (ASD), Prader-Willi Syndrome (PWS), or Phelan-McDermid Syndrome (PMS).
- To assess the impact of intranasal OXT on irritability and related neural mechanisms in these pediatric populations.
- To identify areas for future research regarding OXT's efficacy, dosing, and safety in pediatric psychopathology.
Main Methods:
- Mini-review of fifteen randomized controlled trials (RCTs).
- Focus on pediatric patients diagnosed with ASD, PWS, or PMS.
- Analysis of reported changes in irritability, adverse events, and neuroimaging findings.
Main Results:
- Most studies featured small sample sizes and varied OXT dosages.
- Irritability changes were frequently noted as adverse events.
- Neuroimaging revealed OXT's modulation of reward processing and social-emotional neural networks.
Conclusions:
- Intranasal OXT may modulate neural systems involved in social-emotional processing, with potential implications for youth irritability.
- Current research is limited by small sample sizes and inconsistent methodologies.
- Further investigation is crucial to establish optimal OXT dosing, duration, target populations, and safety profiles for clinical application.
Abstract:
Endogenous neuropeptide Oxytocin (OXT) plays a crucial role in modulating pro-social behavior and the neural response to social/emotional stimuli. Intranasal administration is the most common method of delivering OXT. Intranasal OXT has been implemented in clinical studies of various psychiatric disorders with mixed results, mainly related to lack of solid pharmacodynamics and pharmacokinetics model. Due to intranasal OXT's mechanism of reducing the activation of neural areas implicated in emotional responding and emotion regulation, a psychopathology with this target mechanism could be potentially excellent candidate for future clinical trial. In this regard, irritability in youth may be a very promising target for clinical studies of intranasal OXT. Here we provide a mini-review of fifteen randomized controlled trials in pediatric patients with diagnoses of autism spectrum disorder (ASD), Prader-Willi syndrome (PWS), or Phelan-McDermid syndrome (PMS). Most studies had small sample sizes and varying dosages, with changes in irritability, mainly as adverse events (AEs). Neuroimaging results showed modulation of the reward processing system and the neural areas implicated in social-emotional information processing by intranasal OXT administration. Further research is needed to determine the most effective dose and duration of OXT treatment, carefully select target psychopathologies, verify target engagement, and measure adverse event profiles.
